T2ND34 Stock Overview
A medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Tandem Diabetes Care, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.06 |
| 52 Week High | US$18.90 |
| 52 Week Low | US$6.16 |
| Beta | 1.37 |
| 11 Month Change | -13.80% |
| 3 Month Change | -32.73% |
| 1 Year Change | 75.56% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -73.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| T2ND34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | -3.1% | -0.4% | 0.3% |
| 1Y | 75.6% | 14.8% | -1.7% |
Return vs Industry: T2ND34 exceeded the BR Medical Equipment industry which returned 15.3% over the past year.
Return vs Market: T2ND34 exceeded the BR Market which returned -1.6% over the past year.
Price Volatility
| T2ND34 volatility | |
|---|---|
| T2ND34 Average Weekly Movement | 8.6% |
| Medical Equipment Industry Average Movement | 7.0% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in BR Market | 8.3% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: T2ND34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: T2ND34's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of BR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 2,400 | John Sheridan | www.tandemdiabetes.com |
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body.
Tandem Diabetes Care, Inc. Fundamentals Summary
| T2ND34 fundamental statistics | |
|---|---|
| Market cap | R$10.57b |
| Earnings (TTM) | -R$731.96m |
| Revenue (TTM) | R$4.93b |
2.3x
P/S Ratio-15.6x
P/E RatioIs T2ND34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| T2ND34 income statement (TTM) | |
|---|---|
| Revenue | US$854.35m |
| Cost of Revenue | US$428.94m |
| Gross Profit | US$425.41m |
| Other Expenses | US$552.20m |
| Earnings | -US$126.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.93 |
| Gross Margin | 49.79% |
| Net Profit Margin | -14.84% |
| Debt/Equity Ratio | 146.6% |
How did T2ND34 perform over the long term?
See historical performance and comparison